Dalfampridine (4-aminopyridine extended-release) is a broad-spectrum potassium-channel blocker that improves axonal conduction in demyelinated nerve fibres, used to improve walking speed in multiple sclerosis patients. Simson Pharma's Dalfampridine reference standard and impurities support stability-indicating testing for this neurological therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dalfampridine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.